{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:11:22Z","timestamp":1776723082698,"version":"3.51.2"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Faculty of Pharmacy, Silpakorn University","award":["003\/2564"],"award-info":[{"award-number":["003\/2564"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Apixaban and amiodarone are drugs used for non-valvular atrial fibrillation (NVAF) in routine practice. The evidence about apixaban plasma levels in patients who receive apixaban with amiodarone, including bleeding outcomes, has been limited. This study aimed to compare the apixaban plasma levels and bleeding outcomes between apixaban monotherapy and apixaban with amiodarone groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This study was a prospective, observational, and single-center research which was conducted from January 2021 to January 2022 in NVAF patients who received apixaban at a tertiary care hospital located in the center of Bangkok, Thailand.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Thirty-three patients were measured for their median (5<jats:sup>th<\/jats:sup>\u201395<jats:sup>th<\/jats:sup> percentile) apixaban plasma levels. The trough of apixaban plasma level (C<jats:sub>trough<\/jats:sub>) were 108.49 [78.10\u2013171.52] and 162.05 [87.94\u2013292.88] \u03bcg\/L in the apixaban monotherapy and apixaban with amiodarone groups, respectively (p = 0.028). Additionally, the peaks of apixaban plasma level (C<jats:sub>peak<\/jats:sub>) were 175.36 [122.94\u2013332.34] and 191 [116.88\u2013488.21] \u03bcg\/L in the apixaban monotherapy and apixaban with amiodarone groups, respectively (p = 0.375). There was bleeding that occurred in 7 patients (21.21%); 5 patients in the apixaban monotherapy group and 2 patients in the apixaban with amiodarone group, respectively.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Amiodarone may increase the peaks and troughs of apixaban plasma levels. The co-administration of apixaban with amiodarone is generally well tolerated. However, the careful observation of bleeding symptoms in individual cases is necessary to ensure safety.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0295511","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T18:49:28Z","timestamp":1705690168000},"page":"e0295511","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Does amiodarone impact on apixaban levels? The effect of amiodarone on apixaban level among Thai patients with non-valvular Atrial Fibrillation"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3538-5353","authenticated-orcid":true,"given":"Sutee","family":"Limcharoen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarawuth","family":"Limprasert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8650-0924","authenticated-orcid":true,"given":"Pornwalai","family":"Boonmuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manat","family":"Pongchaidecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juthathip","family":"Suphanklang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weerayuth","family":"Saelim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wichai","family":"Santimaleeworagun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyarat","family":"Pimsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"pone.0295511.ref001","doi-asserted-by":"crossref","first-page":"100709","DOI":"10.1016\/j.ijcha.2020.100709","article-title":"Atrial fibrillation prevalence and risk profile from novel community-based screening in Thailand: A prospective multi-centre study","volume":"32","author":"NC Suwanwela","year":"2021","journal-title":"IJC Heart & Vasculature"},{"issue":"1","key":"pone.0295511.ref002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ccep.2013.10.007","article-title":"Mechanisms of Stroke in Atrial Fibrillation","volume":"6","author":"JM Castellano","year":"2014","journal-title":"Card Electrophysiol Clin"},{"issue":"3\u20134","key":"pone.0295511.ref003","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000502971","article-title":"Newly Detected Atrial Fibrillation after Acute Stroke: A Narrative Review of Causes and Implications","volume":"144","author":"Y Wang","year":"2019","journal-title":"Cardiology"},{"issue":"5","key":"pone.0295511.ref004","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"G Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"pone.0295511.ref005","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.05.017","article-title":"A Narrative Review of Nonvitamin K Antagonist Oral Anticoagulant Use in Secondary Stroke Prevention","volume":"28","author":"V Caso","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"11","key":"pone.0295511.ref006","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"CB Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0295511.ref007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12325-012-0003-2","article-title":"Apixaban: an oral direct factor-xa inhibitor","volume":"29","author":"D Jim\u00e9nez","year":"2012","journal-title":"Adv Ther"},{"key":"pone.0295511.ref008","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1136\/bmj.k2505","article-title":"Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care","volume":"362","author":"Y Vinogradova","year":"2018","journal-title":"BMJ"},{"issue":"10","key":"pone.0295511.ref009","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review","volume":"58","author":"W Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"4, Part 2","key":"pone.0295511.ref010","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/0002-8703(83)90006-6","article-title":"Amiodarone pharmacokinetics","volume":"106","author":"DW Holt","year":"1983","journal-title":"Am Heart J"},{"issue":"3","key":"pone.0295511.ref011","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.19102\/icrm.2019.100304","article-title":"Clinically Important Drug-Drug Interactions Between Antiarrhythmic Drugs and Anticoagulants","volume":"10","author":"KM Konieczny","year":"2019","journal-title":"J Innov Card Rhythm Manag"},{"issue":"11","key":"pone.0295511.ref012","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1124\/dmd.115.065623","article-title":"P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms","volume":"43","author":"MG McDonald","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"pone.0295511.ref013","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jacc.2019.12.068","article-title":"Select Drug-Drug Interactions With Direct Oral Anticoagulants","volume":"75","author":"BS Wiggins","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"pone.0295511.ref014","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"23","author":"J Steffel","year":"2021","journal-title":"Europace"},{"issue":"5","key":"pone.0295511.ref015","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/jcpt.13596","article-title":"Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins","volume":"47","author":"E. Milner","year":"2022","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"pone.0295511.ref016","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10840-018-0427-y","article-title":"Clinical outcomes in patients with atrial fibrillation receiving amiodarone on NOACs vs. warfarin","volume":"54","author":"R. Avendano","year":"2019","journal-title":"J Interv Card Electrophysiol"},{"issue":"5","key":"pone.0295511.ref017","doi-asserted-by":"crossref","first-page":"e00647","DOI":"10.1002\/prp2.647","article-title":"Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports","volume":"8","author":"S Fernandez","year":"2020","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"pone.0295511.ref018","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11239-019-01962-2","article-title":"Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care","volume":"49","author":"M Gulilat","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"13","key":"pone.0295511.ref019","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation","volume":"318","author":"SH Chang","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"pone.0295511.ref020","doi-asserted-by":"crossref","first-page":"769","DOI":"10.7326\/M22-3238","article-title":"Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation: A Retrospective Cohort Study","volume":"176","author":"WA Ray","year":"2023","journal-title":"Ann Intern Med"},{"issue":"11","key":"pone.0295511.ref021","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/psp4.12347","article-title":"Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation","volume":"7","author":"B Cirincione","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"pone.0295511.ref022","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"4","key":"pone.0295511.ref023","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11239-018-1738-7","article-title":"Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients","volume":"46","author":"B Hirsh Raccah","year":"2018","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"pone.0295511.ref024","doi-asserted-by":"crossref","first-page":"13908","DOI":"10.1038\/s41598-021-93372-9","article-title":"Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation","volume":"11","author":"A Mavri","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"pone.0295511.ref025","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12114","article-title":"Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects","volume":"76","author":"VV Upreti","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"pone.0295511.ref026","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/jcph.633","article-title":"Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban","volume":"56","author":"M Chang","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"15","key":"pone.0295511.ref027","first-page":"1541","article-title":"Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"64","author":"G Flaker","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"pone.0295511.ref028","first-page":"e13486","article-title":"Possible Drug-Drug Interaction Between Eliquis and Amiodarone Resulting in Hemopericardium","volume":"13","author":"A Olagunju","year":"2021","journal-title":"ACureus"},{"issue":"3","key":"pone.0295511.ref029","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cjco.2021.11.002","volume":"4","author":"K Hill","year":"2022","journal-title":"CJC open"},{"issue":"4","key":"pone.0295511.ref030","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s11239-020-02037-3","article-title":"The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding","volume":"49","author":"S Hanigan","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"pone.0295511.ref031","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1097\/FJC.0000000000001038","article-title":"Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study","volume":"78","author":"I \u0160kor\u0148ov\u00e1","year":"2021","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T18:49:53Z","timestamp":1705690193000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295511"}},"subtitle":[],"editor":[{"given":"Nienke","family":"van Rein","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0295511","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]}}}